Trials / Unknown

UnknownNCT05553379

Vivatmo proTM EU-study: FeNO Monitoring in Asthmatic Patients Responding to ICS Treatment

Clinical Study of the Vivatmo proTM for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in Asthmatic Patients Responding to Inhaled Corticosteroid (ICS) Treatment

Status: Unknown
Phase: —
Study type: Observational
Enrollment: 48 (actual)

Sponsor: Bosch Healthcare Solutions GmbH · Industry
Sex: All
Age: 7 Years – 80 Years
Healthy volunteers: —

Summary

This is a multi-center study to evaluate fractional exhaled nitric oxide (FeNO) measured with the Vivatmo pro in adult and pediatric subjects.

Detailed description

Subjects will be screened, enrolled and tested at Study Visit #1 and then prescribed inhaled corticosteroid (ICS) treatment as per routine clinical care. Subjects will return for Study Visit #2 in two weeks and repeat fractional exhaled nitric oxide (FeNO) measured with the Vivatmo pro,

Conditions

Asthma

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	FeNO measurement	FeNO measurement at each visit

Timeline

Start date: 2022-03-15
Primary completion: 2022-09-15
Completion: 2022-10-15
First posted: 2022-09-23
Last updated: 2022-09-23

Locations

5 sites across 2 countries: Czechia, Germany

Regulatory

FDA-regulated device study

Source: ClinicalTrials.gov record NCT05553379. Inclusion in this directory is not an endorsement.